Cytokines in the cerebrospinal fluids of patients with chronic fatigue syndrome/myalgic encephalomyelitis.
Peterson, D, Brenu, E W, Gottschalk, G et al. · Mediators of inflammation · 2015 · DOI
Quick Summary
Researchers tested cerebrospinal fluid (the fluid around the brain and spinal cord) from ME/CFS patients and healthy controls to see if immune chemicals called cytokines were different. Out of 27 different immune chemicals tested, they found that only one—called IL-10—was lower in ME/CFS patients. This suggests that immune system problems in the brain and nervous system may play a role in ME/CFS symptoms.
Why It Matters
This study is one of very few to directly examine immune markers in the cerebrospinal fluid of ME/CFS patients, providing rare evidence that neuroinflammation may be relevant to the condition. Understanding what happens in the brain and spinal fluid is crucial because many ME/CFS patients report cognitive problems and neurological symptoms, suggesting the nervous system itself may be affected.
Observed Findings
IL-10 (an anti-inflammatory cytokine) was significantly reduced in cerebrospinal fluid of CFS/ME patients compared to healthy controls.
The other 26 cytokines examined showed no significant differences between CFS/ME patients and controls.
This was a small pilot study with 18 CFS/ME patients and 5 healthy controls.
CSF samples were analyzed using the Bio-Plex Human Cytokine 27-plex Assay.
Inferred Conclusions
Cerebrospinal fluid cytokine dysregulation may contribute to neurological symptoms in CFS/ME.
Perturbations in inflammatory cytokines in the central nervous system warrant further investigation in ME/CFS.
IL-10 reduction may represent a specific neuroinflammatory marker in some CFS/ME patients.
Remaining Questions
Does IL-10 reduction correlate with severity of neurological or cognitive symptoms in ME/CFS patients?
Why is IL-10 specifically reduced while other anti-inflammatory markers appear normal?
Do IL-10 levels change over time or with treatment response, and could this marker help monitor disease progression?
What This Study Does Not Prove
This pilot study does not prove that low IL-10 causes ME/CFS or explain what role this reduction plays in the disease. The small sample size (18 patients, 5 controls) limits confidence in the findings, and this single significant result among 27 tests raises the possibility of chance findings. Correlation between IL-10 levels and disease severity or symptoms was not examined.
Would a larger study with more controls and more detailed clinical phenotyping confirm this finding and reveal which CFS/ME patient subgroups show this pattern?